INDUSTRY FACT FILE · MEDICAL DEVICES & MEDTECH

Threat Landscape: Top Cyber Threats Facing Connected Medical Devices

The 18 most relevant cyber threats, attacks and industry challenges for connected device manufacturers, diagnostic equipment vendors and remote monitoring platforms.

Medical devices face threats at every layer: firmware flaws and hard-coded credentials, insecure wireless pairing, unsigned updates, exposed debug ports, vulnerable components and cloud platforms that aggregate patient data. Because devices stay in service for years, unpatched vulnerabilities persist across fleets.

Public examples include the 2017 FDA-announced firmware update for about 465,000 pacemakers and the January 2025 US warning about a patient monitor with a hidden function sending data to a hard-coded address—showing both safety and supply-chain dimensions.

The list below is a practical assessment framework, not a statistical ranking. Priority varies by business model, technology exposure and existing controls.

The matrix is a qualitative guide for prioritising the first round of security reviews.

Figure 5: Qualitative threat relevance by medtech segment (Codec Networks assessment).

4.1 Firmware and hidden functions

Embedded firmware and third-party modules can contain vulnerabilities, hard-coded credentials or undocumented functions that customers cannot see.

• Questions to test: Has firmware been analysed for secrets and unexpected behaviour? Is every third-party component listed in an SBOM? Do suppliers commit to security requirements?
• Relevant services: firmware analysis, SBOM and component analysis, supplier assessments.

4.2 Update integrity

Update mechanisms are powerful: whoever controls them controls the fleet. Unsigned updates or poorly protected update servers allow malicious firmware.

• Questions to test: Is firmware cryptographically signed and verified at boot? Is the update server hardened and monitored? Can updates be staged and rolled back?
• Relevant services: secure update review, infrastructure testing, product incident planning.

4.3 Hardware and debug interfaces

Debug ports left enabled and keys shared across units let researchers—or attackers—extract firmware and clone devices.

• Questions to test: Are debug interfaces locked in production? Does each device have a unique identity and protected key storage?
• Relevant services: hardware security testing, provisioning review.

4.4 Wireless, apps and cloud

Wearables and home devices rely on BLE, apps and cloud platforms. Weak pairing, embedded API keys and missing authorisation expose patients' data at scale.

• Questions to test: Is pairing authenticated? Are app secrets protected? Does the platform enforce per-device and per-patient authorisation?
• Relevant services: wireless, mobile app, API and cloud testing.

4.5 Regulatory evidence and post-market

Regulators expect threat models, SBOMs, testing and vulnerability management. Weak evidence delays approvals, and weak post-market processes leave fleets exposed.

• Questions to test: Is there a threat model traceable to risk files? Is there a coordinated disclosure process and patch plan?
• Relevant services: threat modelling, submission evidence, PSIRT and disclosure programme.

• Device regulators: vulnerabilities affecting safety may require field safety corrective actions and regulator communication under CDSCO, FDA or EU rules.
• CERT-In: cyber incidents affecting companies and platforms reported within six hours.
• Privacy: personal data breaches from platforms must be intimated to the Data Protection Board once DPDP breach provisions commence in May 2027.
• Hospitals: customers expect security advisories and patches under procurement terms.
• Researchers: coordinated disclosure affects reputation and timelines.

• Do we have a complete SBOM for every product and version in the field?
• Is our firmware signed and verified at boot, and is our update server hardened?
• Are debug interfaces locked and keys unique per device?
• Does our platform enforce per-device and per-patient authorisation?
• Do we have a coordinated vulnerability disclosure and patch process?
• Is our cybersecurity evidence ready for FDA, EU and CDSCO reviews?

Note: Threat descriptions and relevance ratings are general guidance, not findings about any specific product. Public examples are summarised from widely reported regulator communications.